Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€44.43

€44.43

1.070%
0.47
1.070%
€52.50
 
30.01.26 / Tradegate WKN: BAY001 / Symbol: BAYZF / Name: Bayer / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Bayer AG Stock

Bayer AG gained 1.070% today.
The stock is one of the favorites of our community with 22 Buy predictions and 2 Sell predictions.
With a target price of 52 € there is a slightly positive potential of 17.05% for Bayer AG compared to the current price of 44.43 €.
Our community identified positive and negative aspects for Bayer AG stock for the coming years. 18 users see the criterium "Worthwhile Investment for the next years" as a plus for the Bayer AG stock. On the other hand our users think that "Balance Sheet Risk" could be a problem in the future.

Bayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.

Pros and Cons of Bayer AG in the next few years

Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Bayer AG vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Bayer AG 1.070% -0.225% 20.100% 103.225% 20.100% -21.924% -11.310%
Merck KGaA -1.150% -1.840% 2.535% -17.118% 2.535% -35.043% -8.999%
AbbVie Inc. 2.170% 1.401% -4.175% 11.506% -4.175% 40.113% 122.722%
Pfizer Inc. 2.160% 2.811% 4.840% -13.711% 4.840% -44.447% -24.577%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

Bayer, with its US ticker symbol BAYZF, is a prominent player in the pharmaceuticals industry, boasting a rich history and a diverse portfolio. A deep dive into Bayer's financials reveals a complex picture—while there are some strengths and opportunities for growth, several areas raise concerns.

When analyzing Bayer's financials, several key aspects come into play, revealing both positives and negatives that deserve attention. The company's total assets stood at approximately €123.34 billion in 2023, slightly up from €124.88 billion in 2022. A noticeable highlight is Bayer’s gross profit, which peaked at around €27.8 billion in 2023, reflecting robust revenue generation capabilities even amidst some operational challenges.

*Pros: *

Comments

systinvest hat das Wertpapier Bayer AG in seinem Wikifolio Aktienwertselektion mit System gekauft.
Show more

Data is interesting. Explore smash karts for a perfect market analysis.
Show more

Prediction Buy
Perf. (%) 3.91%
Target price 60.000
Change
Ends at 13.08.23

Target price set to 60.0
Show more

News

Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign


Today Bayer announced it has teamed up with former professional quarterback, Tony Romo, on ‘Highlights REAL,’ a campaign celebrating everyday moments. Tony is joined by his father Ramiro, who has

Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention


Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two late-breaking

Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases
Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases


Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic five-year collaboration agreement to advance innovative therapies from target identification